These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 27467440)
1. Association Between Germline Mutation in VSIG10L and Familial Barrett Neoplasia. Fecteau RE; Kong J; Kresak A; Brock W; Song Y; Fujioka H; Elston R; Willis JE; Lynch JP; Markowitz SD; Guda K; Chak A JAMA Oncol; 2016 Oct; 2(10):1333-1339. PubMed ID: 27467440 [TBL] [Abstract][Full Text] [Related]
2. Germline variant in MSX1 identified in a Dutch family with clustering of Barrett's esophagus and esophageal adenocarcinoma. van Nistelrooij AMJ; van Marion R; van Ijcken WFJ; de Klein A; Wagner A; Biermann K; Spaander MCW; van Lanschot JJB; Dinjens WNM; Wijnhoven BPL Fam Cancer; 2018 Jul; 17(3):435-440. PubMed ID: 29134539 [TBL] [Abstract][Full Text] [Related]
3. Anterior gradient 2 profiling in Barrett columnar epithelia and adenocarcinoma. Pizzi M; Fassan M; Realdon S; Balistreri M; Battaglia G; Giacometti C; Zaninotto G; Zagonel V; De Boni M; Rugge M Hum Pathol; 2012 Nov; 43(11):1839-44. PubMed ID: 22521076 [TBL] [Abstract][Full Text] [Related]
4. The NAD(P)H:quinone oxidoreductase I C609T polymorphism modifies the risk of Barrett esophagus and esophageal adenocarcinoma. di Martino E; Hardie LJ; Wild CP; Gong YY; Olliver JR; Gough MD; Bird NC Genet Med; 2007 Jun; 9(6):341-7. PubMed ID: 17575500 [TBL] [Abstract][Full Text] [Related]
5. Germline mutations in MSR1, ASCC1, and CTHRC1 in patients with Barrett esophagus and esophageal adenocarcinoma. Orloff M; Peterson C; He X; Ganapathi S; Heald B; Yang YR; Bebek G; Romigh T; Song JH; Wu W; David S; Cheng Y; Meltzer SJ; Eng C JAMA; 2011 Jul; 306(4):410-9. PubMed ID: 21791690 [TBL] [Abstract][Full Text] [Related]
6. Familial Barrett esophagus and adenocarcinoma of the gastroesophageal junction. Eng C; Spechler SJ; Ruben R; Li FP Cancer Epidemiol Biomarkers Prev; 1993; 2(4):397-9. PubMed ID: 8348064 [TBL] [Abstract][Full Text] [Related]
8. Barrett associated MHC and FOXF1 variants also increase esophageal carcinoma risk. Dura P; van Veen EM; Salomon J; te Morsche RH; Roelofs HM; Kristinsson JO; Wobbes T; Witteman BJ; Tan AC; Drenth JP; Peters WH Int J Cancer; 2013 Oct; 133(7):1751-5. PubMed ID: 23504527 [TBL] [Abstract][Full Text] [Related]
9. Genetic alterations in Barrett esophagus and adenocarcinomas of the esophagus and esophagogastric junction region. Wu TT; Watanabe T; Heitmiller R; Zahurak M; Forastiere AA; Hamilton SR Am J Pathol; 1998 Jul; 153(1):287-94. PubMed ID: 9665490 [TBL] [Abstract][Full Text] [Related]
11. Genetic variants in Barrett's esophagus and esophageal adenocarcinoma: a literature review. Callahan ZM; Shi Z; Su B; Xu J; Ujiki M Dis Esophagus; 2019 Aug; 32(8):. PubMed ID: 30888413 [TBL] [Abstract][Full Text] [Related]
12. Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma. Buas MF; He Q; Johnson LG; Onstad L; Levine DM; Thrift AP; Gharahkhani P; Palles C; Lagergren J; Fitzgerald RC; Ye W; Caldas C; Bird NC; Shaheen NJ; Bernstein L; Gammon MD; Wu AH; Hardie LJ; Pharoah PD; Liu G; Iyer P; Corley DA; Risch HA; Chow WH; Prenen H; Chegwidden L; Love S; Attwood S; Moayyedi P; MacDonald D; Harrison R; Watson P; Barr H; deCaestecker J; Tomlinson I; Jankowski J; Whiteman DC; MacGregor S; Vaughan TL; Madeleine MM Gut; 2017 Oct; 66(10):1739-1747. PubMed ID: 27486097 [TBL] [Abstract][Full Text] [Related]
14. CDC2/CDK1 expression in esophageal adenocarcinoma and precursor lesions serves as a diagnostic and cancer progression marker and potential novel drug target. Hansel DE; Dhara S; Huang RC; Ashfaq R; Deasel M; Shimada Y; Bernstein HS; Harmon J; Brock M; Forastiere A; Washington MK; Maitra A; Montgomery E Am J Surg Pathol; 2005 Mar; 29(3):390-9. PubMed ID: 15725809 [TBL] [Abstract][Full Text] [Related]
15. DNA copy number profiling in esophageal Barrett adenocarcinoma: comparison with gastric adenocarcinoma and esophageal squamous cell carcinoma. Varis A; Puolakkainen P; Savolainen H; Kokkola A; Salo J; Nieminen O; Nordling S; Knuutila S Cancer Genet Cytogenet; 2001 May; 127(1):53-8. PubMed ID: 11408066 [TBL] [Abstract][Full Text] [Related]
16. Expression, localization and polymorphisms of the nuclear receptor PXR in Barrett's esophagus and esophageal adenocarcinoma. van de Winkel A; Menke V; Capello A; Moons LM; Pot RG; van Dekken H; Siersema PD; Kusters JG; van der Laan LJ; Kuipers EJ BMC Gastroenterol; 2011 Oct; 11():108. PubMed ID: 21977915 [TBL] [Abstract][Full Text] [Related]
17. MicroRNA profile in neosquamous esophageal mucosa following ablation of Barrett's esophagus. Sreedharan L; Mayne GC; Watson DI; Bright T; Lord RV; Ansar A; Wang T; Kist J; Astill DS; Hussey DJ World J Gastroenterol; 2017 Aug; 23(30):5508-5518. PubMed ID: 28852310 [TBL] [Abstract][Full Text] [Related]
18. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma. Wu X; Ajani JA; Gu J; Chang DW; Tan W; Hildebrandt MA; Huang M; Wang KK; Hawk E Cancer Prev Res (Phila); 2013 Mar; 6(3):196-205. PubMed ID: 23466817 [TBL] [Abstract][Full Text] [Related]
19. Toll-like Receptor 2 Signalling and the Lysosomal Machinery in Barrett's Esophagus. Verbeek RE; Siersema PD; Vleggaar FP; Ten Kate FJ; Posthuma G; Souza RF; de Haan J; van Baal JW J Gastrointestin Liver Dis; 2016 Sep; 25(3):273-82. PubMed ID: 27689189 [TBL] [Abstract][Full Text] [Related]
20. Mucin gene expression and cell differentiation in human normal, premalignant and malignant esophagus. Guillem P; Billeret V; Buisine MP; Flejou JF; Lecomte-Houcke M; Degand P; Aubert JP; Triboulet JP; Porchet N Int J Cancer; 2000 Dec; 88(6):856-61. PubMed ID: 11093805 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]